Heidelberg University Hospital

What Heidelberg University Hospital does

Heidelberg University Hospital (Universitätsklinikum Heidelberg) is a public-law academic medical center (Anstalt öffentlichen Rechts) under the State of Baden-Württemberg, organizationally tied to Heidelberg University, which was founded in 1386. The hospital operates 2,589 clinical beds across 43+ specialties with a workforce of 14,544 (including 2,148 physicians and 3,529 nurses), delivering roughly 87,441 inpatient stays and 1,275,241 outpatient visits per year, of which approximately 27,000 are international patients. Its core platform is the National Center for Tumor Diseases (NCT) Heidelberg, integrated with the Heidelberg Ion Beam Therapy Center (HIT, Europe's first combined proton and carbon ion facility, operating since 2009), the Hopp Children's Cancer Center Heidelberg (KiTZ), the European Pancreas Center, the Spinal Cord Injury Center, and a comprehensive transplant program. The hospital is also the first in Germany to hold a special manufacturing license for CAR-T cells in leukemia therapy.

The technology stack is anchored by in-house AI/ML diagnostics developed jointly with the German Cancer Research Center (DKFZ) and KiTZ: the DNA methylation classifier (updated in 2025 to cover 184 CNS tumor types, trained on ~7,500 tumor samples, with 160,000+ brain tumor samples analyzed globally) and Hetairos, a histology-based AI classifier of 100+ CNS tumor subtypes that reduces diagnostic turnaround from ~12 days to 12 minutes and outperforms experienced neuropathologists (68% top-1 vs. 30%; 84% top-3 vs. 50%). The methylation classifier is commercialized via the 2022 spin-off Heidelberg Epignostix GmbH. The hospital co-develops nuclear medicine capabilities with the EU Joint Research Centre, including production and clinical use of Actinium-225 for targeted alpha therapy (>700 prostate cancer patients since 2014), and partners with Immatics on a planned first-in-pediatrics Phase 1/2 PRAME TCR-T basket study at KiTZ.

The revenue model combines German DRG-based statutory billing (including EU S2/E112 pathway patients), self-pay international patients who prepay an estimate based on the German DRG plus daily nursing and elective physician rates (with final settlement ~6 weeks post-discharge), direct billing to international insurers (Allianz Worldwide Care, AXA PPP International, Cigna Global Health Benefits) and Gulf embassies (Saudi Arabia, Kuwait, Oman) under cost guarantee, and a growing fee-for-service private outpatient layer (e.g., the new cardiology clinic, 2026). International patient flow is driven by a dedicated Medical International Office and supported by the Heidelberg Marketing concierge channel; interpreter services are pass-through (€60–€95/hour). Heidelberg ranked 12th in Newsweek/Statista's World's Best Hospitals 2026 and top-100 across all 12 evaluated specialties, with two researchers awarded the 2026 German Cancer Prize.

Name

Heidelberg University Hospital

Legal name

Universitätsklinikum Heidelberg (Heidelberg University Hospital), Anstalt öffentlichen Rechts (Public Law Institution)

Website

https://heidelberg-university-hospital.com

Company type

Private

Operating status

Operating

Headcount range

101–250 employees

Short description

Heidelberg University Hospital is a public-law academic medical center in Heidelberg, Germany, treating ~87,441 inpatients, 1,275,241 outpatients, and ~27,000 international patients annually across 43 specialties, anchored by the National Center for Tumor Diseases, Europe's first proton/carbon ion therapy center, and the first German hospital with a CAR-T manufacturing license.

Ownership category

akta.pro rank

Product category

Academic Hospital Services (University Tertiary Care)

NAICS

General Medical and Surgical Hospitals (62211), Medical Laboratories (621511), Diagnostic Imaging Centers (621512)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Thoracic (Lung) Oncology (HLAKAFAL), Oncology & Specialty Treatment Travel Agencies (THAKAIAI)

Keywords

• University hospital services
• Oncology treatment center
• Radiation therapy services
• International patient services
• Transplantation services

Headquarters

HQ city

Heidelberg

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

1. Self-paying private international patients: International patients receive a treatment plan and a non-binding cost estimate (preliminary invoice) based on the German DRG system for inpatient services plus daily nursing care rates and optional physician choice ("Wahlarzt") services. Patients prepay the estimated amount before treatment begins; final settlement occurs approximately six weeks after treatment ends.
2. Statutory health insurance / EU S2 pathway billing: For EU patients holding statutory insurance (form S2/E112), the hospital accepts the German cost-coverage order (Kostenübernahmebescheid) from a German statutory insurer chosen by the patient; services are settled directly with the insurer, subject to a €10 per day patient co-payment for up to 28 inpatient days.
3. Embassy and international insurer payment guarantees: Recognized without prepayment for select payors including embassies of Saudi Arabia, Kuwait, and Oman, and international insurers such as Allianz Worldwide Care, AXA PPP International, Cigna Global Health Benefits, and EU-SVA/EHIC/S2, subject to submission of a cost guarantee prior to treatment.
4. Private outpatient clinic services: Recently opened private outpatient cardiology clinic providing cardiac MRI, stress echocardiography, cardiac ultrasound, and preoperative risk assessments for self-paying patients, reducing wait times for specialist consultations.
5. Certified medical interpreter services (pass-through): Hospital-certified interpreters bill patients directly at market rates of €60–€95 per hour for common languages; the hospital does not take a commission.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Heidelberg University Hospital is a state-owned academic medical center that delivers comprehensive inpatient and outpatient diagnosis and treatment across 43+ clinical specialties, anchored by flagship programs in oncology (National Center for Tumor Diseases), radiation therapy (proton/carbon ion therapy), pediatric oncology (KiTZ), neurology, cardiology, and transplantation. It generates clinical service revenue from German statutory/DRG billing, EU S2 pathway, self-paying international patients, and direct embassy/insurer payment guarantees, while also operating a dedicated Medical International Office that handles inquiries, case management, interpreter coordination, and telemedicine (DICOM) portals for foreign patients. Beyond direct care, the hospital co-develops proprietary AI-based diagnostic systems (DNA methylation classifier for 184 CNS tumor types, Hetairos histology classifier) and operates the first German in-house CAR-T cell manufacturing license.

Product overview

Heidelberg University Hospital is a platform-plus-modules academic medical center delivering comprehensive inpatient and outpatient care across 43+ clinical specialties, anchored by several flagship specialty centers: the National Center for Tumor Diseases (NCT) Heidelberg (the core oncology program) integrates the European Pancreas Center, Heidelberg Ion Beam Therapy (HIT) proton and carbon ion therapy (Europe's first, operational since 2009), radiation therapy, hematology/oncology/rheumatology, and stem cell transplantation. Pediatric oncology is delivered through the Hopp Children's Cancer Center Heidelberg (KiTZ), which collaborates with DKFZ on the methylation classifier (commercialized via spin-off Heidelberg Epignostix GmbH) and serves as the site for novel TCR T-cell therapies (e.g., Immatics PRAME TCR). Neurology/neurosurgery spans the Spinal Cord Injury Center, stroke and complex neurological treatments, multiple sclerosis/neuroimmunology, and neuroradiology procedures (including coiling therapy for brain aneurysms). Cardiology offers heart surgery, interventional cardiology/catheterization, vascular surgery, and pediatric cardiac care, with a new private outpatient cardiology clinic launched in 2026. The hospital was the first in Germany to receive a special manufacturing license for CAR-T cells in leukemia therapy. AI-driven diagnostics include the Hetairos AI brain tumor classification system (developed with DKFZ) and the DKFZ/KiTZ methylation classifier (updated 2025 to classify 184 CNS tumor types). The Medical International Office serves as a dedicated patient services platform for foreign patients, handling treatment inquiries, case management, interpreter coordination, and financial administration. In 2026, the hospital ranked 12th in Newsweek's World's Best Hospitals and placed in the top 100 globally across all 12 evaluated specialist areas.

Differentiator

Problem solved

Functional benefit

Brands

• National Center for Tumor Diseases (NCT) Heidelberg / Nationales Centrum für Tumorerkrankungen: Interdisciplinary oncology center for cancer treatment at Heidelberg University Hospital.
• Hopp Children's Cancer Center Heidelberg (KiTZ)
• Heidelberg Ion Beam Therapy Center (HIT)
• Heidelberg Epignostix GmbH

Products and services

• National Center for Tumor Diseases (NCT) Heidelberg Interdisciplinary oncology center providing comprehensive cancer treatment including Da Vinci robotic surgery, proton and carbon ion therapy, CyberKnife, modern photon radiotherapy, chemotherapy, immunotherapy, stem cell transplantation (autologous and allogeneic), and supportive care. Treats all cancer types in children and adults via multidisciplinary tumor boards.
• Heidelberg Ion Beam Therapy Center (HIT) — Proton and Carbon Ion Therapy Europe's first combined proton and carbon ion therapy center, operational since 2009, providing highly precise radiotherapy for specific cancer types including chordomas, chondrosarcomas, and other complex tumors. Features gantry-based particle therapy.
• European Pancreas Center Dedicated center for the treatment of pancreatic diseases, including pancreatic cancer, integrated within the National Center for Tumor Diseases.
• Hopp Children's Cancer Center Heidelberg (KiTZ) Pediatric oncology center jointly operated by DKFZ and Heidelberg University Hospital. Site of the PRAME TCR T-cell experimental treatment case (2026) and planned first-in-pediatrics Phase 1/2 basket study for PRAME TCR T-cell therapy candidates. Co-developer of the AI methylation classifier for childhood brain tumors.
• DKFZ/KiTZ AI Methylation Classifier (commercialized via Heidelberg Epignostix GmbH) AI-based DNA methylation classifier for central nervous system tumor diagnosis, commercialized as a diagnostic product in 2022 via spin-off Heidelberg Epignostix GmbH. The updated version (2025) classifies 184 tumor types with probability scores, trained on ~7,500 tumor samples, and has been used to analyze over 160,000 brain tumor samples globally.
• Hetairos AI Brain Tumor Diagnostic System AI system developed by DKFZ and Heidelberg University Hospital that classifies over 100 molecular subtypes of central nervous system tumors from standard histological slides. Reduces diagnostic turnaround from ~12 days to 12 minutes; achieved 68% top-1 accuracy (vs. 30% for neuropathologists) and 84% top-3 accuracy (vs. 50%) in head-to-head comparison against five experienced neuropathologists.
• Spinal Cord Injury Center Dedicated center for the treatment of spinal cord injuries and related conditions.
• Coiling Therapy for Brain Aneurysms Endovascular coiling procedure for treating brain aneurysms using miniature platinum coils inserted via femoral artery catheterization, including balloon-remodeling and stent-assisted coiling techniques. Performed by the Neuroradiology Department in interdisciplinary collaboration with Neurology and Neurosurgery.
• Stem Cell Transplantation Program Autologous and allogeneic stem cell transplantation for leukemia, lymphoma, multiple myeloma, and select severe autoimmune diseases. Available only for hematological/oncological and severe autoimmune conditions.
• Kidney and Liver Transplantation (Living Donor) Living-donor kidney and liver transplantation services.
• Targeted Alpha Therapy (TAT) with Actinium-225 Joint capability with the EU Joint Research Centre for the production and clinical use of the alpha-emitting radioisotope Actinium-225, used to treat over 700 prostate cancer patients since 2014. Targeted alpha therapy uses alpha particles to selectively destroy cancer cells while sparing healthy tissue.
• In-house CAR-T Cell Manufacturing and Therapy First German hospital with a special manufacturing license for CAR-T cells in leukemia therapy, enabling in-house production and administration of CAR-T cell therapies to patients.
• PRAME-directed TCR T-Cell Therapy (Immatics collaboration) Individual experimental treatment with PRAME-directed TCR T-cell therapy delivered at KiTZ/Heidelberg University Hospital, demonstrating deep remission in advanced pediatric nephroblastoma with multi-site metastases.
• Medical International Office — International Patient Services Dedicated administrative service for international patients offering treatment inquiry processing, case management, visa support, appointment scheduling, certified medical interpreter coordination (€60–€95/hour), financial/billing management, telemedicine portal for DICOM uploads, and post-treatment medical reports in English. Serves international patients from over 1,100 cases annually (English site snapshot).
• Online Second Opinion and Video Consultation (Hematology, Oncology, Rheumatology) Remote second-opinion and video consultation service for leukemia, multiple myeloma, lymphoma, sarcoma, and cancer of unknown primary, accessed via cancer-heidelberg.com.
• Private Outpatient Cardiology Clinic Private outpatient cardiology clinic offering cardiac MRI, stress echocardiography, cardiac ultrasound, and preoperative risk assessments for self-paying patients to reduce wait times for specialist consultations.
• Heart Surgery / Cardiac Surgery Program Cardiac surgery program within the Heart and Vascular Diseases department at Heidelberg University Hospital, including pediatric heart surgery, vascular surgery, and interventional cardiology/catheterization services.

Quantifiable outcome

• AI classifier (Hetairos) reduced CNS tumor diagnostic turnaround from approximately 12 days to 12 minutes and achieved 68% accuracy (84% top-3) vs 30% (50% top-3) for five experienced neuropathologists
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered flagship and core.

• German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)flagshipStrategic or Co-development PartnerWorld-renowned research partner located in Heidelberg; together with Heidelberg University and the Hopp Children's Cancer Center Heidelberg (KiTZ), DKFZ and the hospital jointly developed and continuously update the AI-based DNA methylation classifier for CNS tumor diagnosis (covering 184 tumor types). Also collaborates on Actinium-225 production for targeted alpha therapy and joint translational oncology programs.
• National Center for Tumor Diseases (NCT) HeidelbergflagshipStrategic or Co-development PartnerJoint oncology program with DKFZ and Heidelberg University Hospital; provides interdisciplinary tumor board evaluation and individualized therapy planning for all cancer types (including pediatric, hematologic, and rare cancers).
• Hopp Children's Cancer Center Heidelberg (KiTZ)flagshipStrategic or Co-development PartnerJoint pediatric oncology center combining care and research at Heidelberg University Hospital and DKFZ; site of the recent PRAME-directed TCR-T experimental treatment case and planned first-in-pediatrics Phase 1/2 basket study for Immatics' PRAME TCR-T candidates.
• Heidelberg University (Ruprecht-Karls-Universität Heidelberg)flagshipStrategic or Co-development PartnerAcademic partner whose Faculty of Medicine is co-located with the hospital; staff are scientifically active and conduct research alongside clinical duties; involved in AI methylation classifier development and other translational programs.
• European Commission Joint Research Centre (JRC)coreStrategic or Co-development PartnerJoint capability for the production and clinical use of the alpha-emitting radioisotope Actinium-225; breakthrough achieved in 2013 enabled production for clinical trials, with over 700 prostate cancer patients treated since 2014. New collaboration agreements signed with South African hospitals in 2025 to accelerate cancer diagnosis, treatment, and medical radioisotope production.
• Heidelberg Epignostix GmbHcoreOEM/ Whitelabel/ Licensing PartnerUniversity hospital spin-off that commercializes the AI-based DNA methylation classifier as a diagnostic product since 2022; tool is used to analyze over 160,000 brain tumor samples globally.
• Heidelberg Marketing GmbHcoreChannel Partner/ Reseller/ DistributorTourism and concierge partner that handles hotel bookings, airport transfers from Frankfurt or Stuttgart, city tours, and HeidelbergCARD distribution for international patients and accompanying persons.
• ImmaticscoreStrategic or Co-development PartnerBiotech partner whose PRAME-directed TCR T-cell therapy was administered in an individual experimental treatment at KiTZ and Heidelberg University Hospital, achieving deep remission in a 17-year-old with advanced nephroblastoma; Immatics plans to evaluate its candidates in a first-in-pediatrics Phase 1/2 basket study at the KiTZ center.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Charité - Universitätsmedizin Berlin: Germany's other flagship university hospital and one of Europe's largest academic medical centers, with comparable scale (~24,000 employees), translational research depth, and a similar public-law institutional structure. Directly comparable on oncology, neurology, and international patient services.
• University Hospital Zurich (Universitätsspital Zürich): Swiss academic medical center with similar specialty-center model (comprehensive cancer, neuro, cardiac), strong translational research ties to ETH/University of Zurich, and a sizable international private-patient segment — comparable on premium tertiary care and research-driven reputation.
• Karolinska University Hospital: Sweden's premier academic hospital, tied to the Karolinska Institute, with similar oncology/neuroscience depth, public ownership, and a track record of high-impact research partnerships (incl. with the Nobel Assembly). Comparable on academic medical-center positioning and European tertiary-care leadership.
• Mayo Clinic: U.S. non-profit academic medical center consistently ranked #1 in World's Best Hospitals and a global benchmark for international patient services. Comparable on premium tertiary care, translational research, AI diagnostics investment, and large cross-border patient flow.
• Memorial Sloan Kettering Cancer Center: U.S. specialty cancer center with deep CAR-T, TCR-T, and translational research programs and a sizable international patient program. Directly comparable on flagship oncology positioning and advanced cellular therapy capability.
• MD Anderson Cancer Center: U.S. comprehensive cancer center with deep CAR-T/TCR-T and proton-therapy programs and a large international patient office. Directly comparable on flagship oncology positioning, advanced cellular therapy capability, and medical-tourism infrastructure.

Broad incumbents

• Johns Hopkins Hospital: Top-ranked U.S. academic medical center with comparable translational research engine, oncology/neurosurgery depth, and a sizable international patient office. Comparable on reputation, research depth, and high-acuity case mix.
• Cleveland Clinic: Multi-specialty U.S. health system with a major international footprint (Cleveland Clinic Abu Dhabi, London) and an established international patient office. Broader portfolio than Heidelberg but directly comparable on cardiac surgery, oncology, neurology, and premium international services.

Emerging players

• Bumrungrad International Hospital: Thai-listed private hospital and one of the largest medical-tourism platforms globally, treating over a million patients annually including a heavy international mix. Comparable on cross-border patient flow, dedicated international office, and premium pricing for complex cases.

Others

• National Center for Tumor Diseases (NCT) partners / DKFZ: DKFZ is Heidelberg's flagship translational research partner (not a direct competitor) but operates related cancer research infrastructure across Germany. Included as an ecosystem peer reflecting the joint development of methylation classifier, TAT, and TCR-T programs that anchor Heidelberg's differentiation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=f5uEmdunSD4
• Xx.com/uniklinik_hd
• Facebookfacebook.com/profile.php

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Heidelberg University Hospital